Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Telix Pharmaceuticals Limited (TLX) - Net Assets
Latest net assets as of December 2025: $622.27 Million USD
Based on the latest financial reports, Telix Pharmaceuticals Limited (TLX) has net assets worth $622.27 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.77 Billion) and total liabilities ($1.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $622.27 Million |
| % of Total Assets | 35.14% |
| Annual Growth Rate | 18.44% |
| 5-Year Change | 16986.07% |
| 10-Year Change | N/A |
| Growth Volatility | 692.03 |
Telix Pharmaceuticals Limited - Net Assets Trend (2000–2025)
This chart illustrates how Telix Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Telix Pharmaceuticals Limited (2000–2025)
The table below shows the annual net assets of Telix Pharmaceuticals Limited from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $622.27 Million | +9.51% |
| 2024-12-31 | $568.21 Million | +281.58% |
| 2023-12-31 | $148.91 Million | +74.69% |
| 2022-12-31 | $85.25 Million | +2240.61% |
| 2021-12-31 | $3.64 Million | -95.39% |
| 2020-12-31 | $79.02 Million | +11.71% |
| 2019-12-31 | $70.73 Million | +33.70% |
| 2018-12-31 | $52.90 Million | +7.33% |
| 2017-12-31 | $49.29 Million | +2883.99% |
| 2016-12-31 | $-1.77 Million | -727.63% |
| 2015-12-31 | $-213.93K | +90.16% |
| 2014-12-31 | $-2.17 Million | -244.48% |
| 2013-12-31 | $1.50 Million | +113.12% |
| 2011-12-31 | $-11.46 Million | -226.75% |
| 2000-12-31 | $9.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Telix Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22543437600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $719.03 Million | 115.55% |
| Other Comprehensive Income | $134.76 Million | 21.66% |
| Total Equity | $622.27 Million | 100.00% |
Telix Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Telix Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mineral Res
PINK:MALRY
|
$2.53 Billion |
|
Kokuyo Co., Ltd.
PINK:KUKYF
|
$2.53 Billion |
|
Acushnet Holdings Corp
NYSE:GOLF
|
$2.54 Billion |
|
Alupar Investimento SA
SA:ALUP11
|
$2.54 Billion |
|
Frasers Centrepoint Trust
PINK:FRZCF
|
$2.53 Billion |
|
Digitalbridge Group Inc
NYSE:DBRG
|
$2.53 Billion |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
$2.53 Billion |
|
Operadora de Sites Mexicanos S.A. de C.V
PINK:OPMXF
|
$2.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Telix Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 568,213,000 to 622,274,784, a change of 54,061,784 (9.5%).
- Net loss of 10,685,154 reduced equity.
- New share issuances of 1,808,000 increased equity.
- Other comprehensive income decreased equity by 49,641,909.
- Other factors increased equity by 112,580,847.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.69 Million | -1.72% |
| Share Issuances | $1.81 Million | +0.29% |
| Other Comprehensive Income | $-49.64 Million | -7.98% |
| Other Changes | $112.58 Million | +18.09% |
| Total Change | $- | 9.51% |
Book Value vs Market Value Analysis
This analysis compares Telix Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.34x to 5.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.23 | $9.20 | x |
| 2011-12-31 | $-0.15 | $9.20 | x |
| 2013-12-31 | $1.19 | $9.20 | x |
| 2014-12-31 | $-1.59 | $9.20 | x |
| 2015-12-31 | $0.00 | $9.20 | x |
| 2016-12-31 | $-0.01 | $9.20 | x |
| 2017-12-31 | $0.39 | $9.20 | x |
| 2018-12-31 | $0.26 | $9.20 | x |
| 2019-12-31 | $0.30 | $9.20 | x |
| 2020-12-31 | $0.31 | $9.20 | x |
| 2021-12-31 | $0.01 | $9.20 | x |
| 2022-12-31 | $0.26 | $9.20 | x |
| 2023-12-31 | $0.46 | $9.20 | x |
| 2024-12-31 | $1.65 | $9.20 | x |
| 2025-12-31 | $1.84 | $9.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Telix Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.89%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 2.85x
- Recent ROE (-1.72%) is above the historical average (-277.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -5.50% | 0.00% | 0.00x | 1.04x | $-1.40 Million |
| 2011 | 0.00% | -10.83% | 1.99x | 0.00x | $-2.32 Million |
| 2013 | -166.56% | -11.96% | 1.13x | 12.33x | $-2.66 Million |
| 2014 | 0.00% | 19.18% | 1.60x | 0.00x | $5.65 Million |
| 2015 | 0.00% | -0.41% | 1.81x | 0.00x | $-110.61K |
| 2016 | 0.00% | -0.15% | 1.58x | 0.00x | $133.06K |
| 2017 | -12.94% | -20.07% | 0.62x | 1.04x | $-11.31 Million |
| 2018 | -26.14% | -7087.06% | 0.00x | 1.45x | $-19.12 Million |
| 2019 | -39.76% | -799.63% | 0.03x | 1.46x | $-34.88 Million |
| 2020 | -56.81% | -861.06% | 0.03x | 2.00x | $-52.79 Million |
| 2021 | -3730.77% | -1059.90% | 0.07x | 50.89x | $-80.73 Million |
| 2022 | -130.09% | -65.01% | 0.61x | 3.26x | $-112.08 Million |
| 2023 | 3.50% | 1.04% | 1.26x | 2.67x | $-9.68 Million |
| 2024 | 8.79% | 6.37% | 0.52x | 2.67x | $-6.90 Million |
| 2025 | -1.72% | -0.89% | 0.68x | 2.85x | $-72.91 Million |
Industry Comparison
This section compares Telix Pharmaceuticals Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $245,106,075
- Average return on equity (ROE) among peers: -28.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Telix Pharmaceuticals Limited (TLX) | $622.27 Million | -5.50% | 1.85x | $2.53 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-215.01K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $1.23 Billion | -63.37% | 1.38x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $39.42 Million |
| ABIVAX Société Anonyme (AAVXF) | $28.77 Million | -143.73% | 2.84x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $679.81 Million |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $182.77 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $79.46 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $222.75K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |